share_log

Comerica Bank Makes New Investment in ZimVie Inc. (NASDAQ:ZIMV)

Comerica Bank Makes New Investment in ZimVie Inc. (NASDAQ:ZIMV)

美國科梅里卡銀行對 ZimVie 公司進行新的投資 (納斯達克:ZIMV)
Defense World ·  2023/02/01 06:22

Comerica Bank purchased a new stake in shares of ZimVie Inc. (NASDAQ:ZIMV – Get Rating) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 16,019 shares of the company's stock, valued at approximately $110,000. Comerica Bank owned about 0.06% of ZimVie as of its most recent SEC filing.

根據該公司最近與美國證券交易委員會的披露,美國科梅里卡銀行在第三季度購買了 ZimVie Inc.(NASDAQ:ZIMV-獲得評級)的新股份。機構投資者購買了公司股票的 16,019 股,價值約為 11 萬美元。在最近的 SEC 備案中,美國科梅里卡銀行擁有 ZimVie 的約 0.06%。

Several other institutional investors have also recently made changes to their positions in the business. US Bancorp DE bought a new stake in shares of ZimVie during the 3rd quarter valued at $36,000. Strs Ohio purchased a new stake in ZimVie in the third quarter worth about $47,000. Allspring Global Investments Holdings LLC bought a new position in shares of ZimVie in the third quarter worth about $71,000. Texas Permanent School Fund purchased a new position in shares of ZimVie during the 3rd quarter valued at about $148,000. Finally, Raymond James & Associates bought a new position in shares of ZimVie during the 3rd quarter valued at approximately $110,000. Institutional investors own 74.29% of the company's stock.

其他一些機構投資者最近也更改了他們在業務中的頭寸。美國銀行公司在第三季度買入了 ZimVie 股份的新股份,價值為 36,000 美元。俄亥俄州斯特爾斯特爾在第三季度購買了 ZimVie 的新股份,價值約為 47,000 美元。全春全球投資控股有限責任公司在第三季度購買了 ZimVie 股份的新頭寸,價值約為 71,000 美元。德克薩斯州永久學校基金在第三季度購買了 ZimVie 股份的新頭寸,價值約為 148,000 美元。最後, 雷蒙德詹姆斯 & 同事在第三季度買了 ZimVie 股份的新頭寸,價值約為 $110,000.機構投資者擁有公司股票的 74.29%。

Get
取得
ZimVie
ZimVie
alerts:
警報:

ZimVie Price Performance

價格表現

Shares of ZIMV stock opened at $9.81 on Wednesday. The stock's 50-day moving average price is $8.97 and its 200-day moving average price is $11.58. ZimVie Inc. has a 12-month low of $6.67 and a 12-month high of $50.40. The company has a quick ratio of 1.48, a current ratio of 2.51 and a debt-to-equity ratio of 0.76.

ZIMV 股票在周三開盤 9.81 美元。該股票的 50 天移動平均價為 8.97 美元,其 200 天移動平均價格為 11.58 美元。Zimvie 公司擁有 12 個月低點 6.67 美元和 12 個月高點為 50.40 美元。該公司的快速比率為 1.48,流動比率為 2.51,債務與權益比率為 0.76。

ZimVie (NASDAQ:ZIMV – Get Rating) last issued its quarterly earnings data on Wednesday, November 9th. The company reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.22. ZimVie had a negative return on equity of 2.75% and a negative net margin of 9.96%. The business had revenue of $214.58 million for the quarter, compared to analysts' expectations of $214.83 million. Analysts expect that ZimVie Inc. will post 1.95 earnings per share for the current year.
ZimVie (納斯達克:ZIMV — 獲得評分) 上週三公佈了其季度收益數據,週三, 11 月 9 日.該公司報告了該季度的每股盈利 0.49 美元,超過 0.27 美元的一致預估值 0.22 美元。ZimVie 的資產回報率為 2.75%,負淨利潤率為 9.96%。該業務本季度的收入為 214.58 億美元,而分析師的預期為 214.83 億美元。分析師預計,ZimVie Inc. 將在本年度公佈每股盈利 1.95。

Analysts Set New Price Targets

分析師設定新的價格目標

Separately, Barclays initiated coverage on shares of ZimVie in a research note on Wednesday, December 21st. They set an "underweight" rating and a $9.00 target price on the stock.

另外,巴克萊在 12 月 21 日星期三的一份研究報告中開始對 ZimVie 股份的報導。他們設定了「體重不足」評級和 9.00 美元的股票目標價格。

ZimVie Profile

ZimVie 檔案

(Get Rating)

(取得評分)

ZimVie Inc, a medical technology company, develops, manufactures, and delivers a portfolio of products and solutions designed to treat a range of spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It offers dental implant systems, prosthetic and abutment products, surgical instrumentation, and kits; bone grafts, barrier membranes, allografts, and collagen wound care products; intraoral scanners; and virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and patient-specific restorative components and intra-oral scanners, as well as spinal fusion implants and instrumentation for various spinal procedures, biologics, and bone healing technologies.

ZimVie Inc 是一家醫療技術公司,致力於開發、製造和提供一系列產品和解決方案,旨在治療一系列脊柱病變,並在全球範圍內支持牙齒置換和修復程序。它提供牙科植入系統,假肢和基台產品,手術儀器和套件; 骨移植,屏障膜,異體移植物和膠原蛋白傷口護理產品; 口腔掃描儀; 和虛擬治療規劃服務,指導手術解決方案,CAD/CAM 工作流系統,以及患者特定的修復組件和口腔內掃描儀,以及脊柱融合植入物和脊柱植入物和治療儀器,各種脊柱植入物和治療技術。

Read More

閱讀更多

  • Get a free copy of the StockNews.com research report on ZimVie (ZIMV)
  • Verizon, Charter Trend Higher In Past Month: Are They Buys Now?
  • Dividend King Sysco: Buying On The Dip
  • Is the 1,600% Rise in Genius Group Stock Justified?
  • After Further Review, Investors Liked Exxon Mobil's Earnings
  • Will Caterpillar Dig Its Way To Another Buying Opportunity?
  • 免費獲取有關 ZIMVIE(ZIMV)的研究報告
  • Verizon 公司, 憲章趨勢在過去一個月較高:他們現在買?
  • 股息國王塞斯科:在下跌的購買
  • 天才集團股票上漲 1,600% 是否合理?
  • 經過進一步審查,投資者喜歡埃克森美孚的收益
  • 卡特彼勒會挖掘其方式到另一個購買機會嗎?

Want to see what other hedge funds are holding ZIMV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ZimVie Inc. (NASDAQ:ZIMV – Get Rating).

想看看還有哪些對沖基金持有 ZIMV? 訪問控股公司獲取有關 ZimVie 公司(納斯達克:ZIMV-獲取評級)的最新 13 樓文件和內幕交易。

Receive News & Ratings for ZimVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZimVie and related companies with MarketBeat.com's FREE daily email newsletter.

接收 ZimVie 日報的最新消息和評分 -在下面輸入您的電子郵件地址,以通過 MarketBeat.com 的免費每日電子郵件通訊接收 ZimVie 及相關公司的最新新聞和分析師評級的簡要每日摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論